Stock 300391 CHANGJIANG PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Changjiang Pharmaceutical Group Co., Ltd.

Equities

300391

CNE100001XN8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
4.05 CNY -5.15% Intraday chart for Changjiang Pharmaceutical Group Co., Ltd. +2.02% -47.67%
29/04 Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
29/04 Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,270 2,547 4,299 5,325 3,416 2,712
Enterprise Value (EV) 1 2,187 2,372 5,151 6,168 4,418 3,534
P/E ratio 22 x -3.81 x 170 x 108 x -147 x -4.48 x
Yield 0.51% - - - - -
Capitalization / Revenue 2.58 x 3.51 x 3.54 x 2.25 x 2.11 x 2.26 x
EV / Revenue 2.48 x 3.27 x 4.24 x 2.61 x 2.73 x 2.95 x
EV / EBITDA 13.9 x -58.2 x 43.2 x 21.6 x 24.7 x 30.5 x
EV / FCF -8.02 x 16.9 x 21.2 x -15 x -14.4 x 8.83 x
FCF Yield -12.5% 5.91% 4.72% -6.67% -6.92% 11.3%
Price to Book 1.58 x 3.36 x 5.53 x 6.44 x 4.27 x 13.9 x
Nbr of stocks (in thousands) 3,50,336 3,50,336 3,50,336 3,50,336 3,50,336 3,50,336
Reference price 2 6.480 7.270 12.27 15.20 9.750 7.740
Announcement Date 29/03/19 27/04/20 27/04/21 27/04/22 27/04/23 29/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 881 725.3 1,215 2,362 1,615 1,198
EBITDA 1 156.8 -40.72 119.4 285.2 178.9 115.7
EBIT 1 116.1 -81.4 78.76 228.6 75.5 79.14
Operating Margin 13.17% -11.22% 6.49% 9.68% 4.67% 6.61%
Earnings before Tax (EBT) 1 116.5 -680.2 58.41 158.3 71.83 -681
Net income 1 102 -669.7 25.32 49.1 -23.27 -605.7
Net margin 11.58% -92.33% 2.08% 2.08% -1.44% -50.57%
EPS 2 0.2949 -1.910 0.0723 0.1402 -0.0664 -1.729
Free Cash Flow 1 -272.6 140.2 243.3 -411.3 -305.8 400.3
FCF margin -30.94% 19.32% 20.04% -17.41% -18.93% 33.42%
FCF Conversion (EBITDA) - - 203.87% - - 345.83%
FCF Conversion (Net income) - - 961.02% - - -
Dividend per Share 2 0.0333 - - - - -
Announcement Date 29/03/19 27/04/20 27/04/21 27/04/22 27/04/23 29/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 852 843 1,002 822
Net Cash position 1 83.1 175 - - - -
Leverage (Debt/EBITDA) - - 7.141 x 2.957 x 5.601 x 7.105 x
Free Cash Flow 1 -273 140 243 -411 -306 400
ROE (net income / shareholders' equity) 8.42% -61.6% 6.02% 10.4% 2.72% -52.7%
ROA (Net income/ Total Assets) 3.58% -2.82% 1.59% 3.21% 1.21% 1.41%
Assets 1 2,850 23,742 1,596 1,529 -1,922 -43,006
Book Value Per Share 2 4.100 2.160 2.220 2.360 2.290 0.5600
Cash Flow per Share 2 1.020 1.170 0.4000 0.3100 0.0500 0.0400
Capex 1 8.84 5.24 18.8 142 51.5 6.79
Capex / Sales 1% 0.72% 1.55% 6.02% 3.19% 0.57%
Announcement Date 29/03/19 27/04/20 27/04/21 27/04/22 27/04/23 29/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CHANGJIANG PHARMACEUTICAL GROUP CO., LTD. Stock Changjiang Pharmaceutical Group Co., Ltd.
-47.67% 196M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300391 Stock
  4. Financials Changjiang Pharmaceutical Group Co., Ltd.